<DOC>
	<DOCNO>NCT00145431</DOCNO>
	<brief_summary>The Torcetrapib project terminate December 2 , 2006 due safety finding . To evaluate efficacy safety lipid drug torcetrapib/atorvastatin subject rare genetically know disorder high cholesterol triglyceride level .</brief_summary>
	<brief_title>Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder .</brief_title>
	<detailed_description>For additional information please call : 1-800-718-1021</detailed_description>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type III</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Torcetrapib</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Diagnosis Familial Dysbetalipoproteinemia ( Fredrickson Type III hyperlipoproteinemia ) Women pregnant lactating , plan become pregnant . Subjects clinically indicate need statin ( HMGCoA reductase inhibitor ) therapy atorvastatin concomitant therapy know lipid alter effect LDLC HDLC include fibrates nicotinic acid Subjects take drug know associate increase risk myositis combination HMGCoA reductase inhibitor Subjects medical condition laboratory abnormality could affect subject safety , preclude evaluation response , render unlikely subject would complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>